Skip to main content
. 2023 Jan 13;31:339–351. doi: 10.1016/j.omtn.2023.01.005

Figure 6.

Figure 6

Mouse/rat C6-siRNA/LNP treatment suppresses MG symptoms in rats

Disease severity (A), body weight change (B), hemolysis (C), and complement C6 expression levels in the liver (D) of MG rats (n = 3/group) treated with PBS, Ctrl-siRNA/LNP, or 0.1 and 1 mg/kg mouse/rat (m/r) C6-siRNA/LNP are shown. (A) Rats received i.v. administration of PBS, 0.1 mg/kg of Ctrl-siRNA/LNP, or 0.01 or 0.1 mg/kg m/r C6-siRNA/LNP on day 0. On day 7, anti-AChR mAb (Mab35, 1 mg/kg) was i.v. administered to rats to induce the symptoms of MG. Disease severity was monitored on days 8 and 9 (B). Body weights of rats treated with PBS, Ctrl-siRNA/LNP, or rat C6-siRNA/LNP were expressed as a ratio of the initial body weight (day 0). (C and D) Blood samples were collected from the jugular vein on days 3, 7, 8, and 9 and livers were collected on day 9 to evaluate the complement hemolytic activity in serum and liver complement C6 mRNA expression levels (rat C6/rat GAPDH). Data are presented as the mean ± SEM. n = 4 in each group; ∗p < 0.05 and ∗∗p < 0.01 versus Ctrl-siRNA/LNP.